Loading
Align Technology Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 Aug 2025.
Align Technology Inc: what insiders have been doing
This page follows insider dealings at Align Technology Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in San Jose, United States. The group dates from 1997. The last twelve months, up to 18 October 2026, brought 19 filings signed by 14 insiders.
All open-market trades in the period are sales: 1 sale worth €1.3M, by 1 insider, with no purchase on record. Morici John filed the largest sale, €1.3M, on 20 February 2026.
Compared with its exchange (5,816 companies, median 19 filings), a count of 19 filings is typical. Our records for Align Technology Inc go back to 2016, with 13 purchases and 24 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 4.03 bn USD of revenue and 410.4 m USD of net income.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
133
Thresholds
n/a
Buy Volume
€12M
13 ops. · all time
Sell Volume
€32M
24 ops. · all time
Who traded when
BuySaleJohn Morici1 sale
Joseph M. Hogan1 buy
Julie Ann Coletti1 buy
Since the insiders bought
- +25.5%Entry US$137.77 · Close at T+365 US$172.89
- +25.5%Entry US$137.77 · Close at T+365 US$172.89
- -13.5%Entry US$297.20 · Close at T+365 US$257.21
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Align Technology Inc Buy (bullish), based on 15 analysts. Average price target: US$208.60.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 5,743 of 24,161 companies
64.8
score / 100
Value53
Quality77
FCF yld4.4%
Earn yld3.7%
EV/EBITDA13.7x
ROE10%
Gross mgn67%
Net mgn10%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$157.58
Analyst consensus
15 analystsBuy
US$170.00Target US$208.60(+32%)US$240.00
Income statement
RevenueUS$4B
Gross profitUS$2.7B67% margin
EBITDAUS$822.7M20% margin
Net incomeUS$410.4M10.0% margin
Valuation
PER (trailing)27.3x
PER (forward)12.6x
P/Book2.7x
Beta1.65
Balance sheet & cash
Market capUS$11.2B
Total debtUS$114.4M
Free Cash FlowUS$490.8M
Debt / Equity3%
Profitability & ownership
ROE10.2%
ROA7.4%
% insiders6.1%
% institutions105.2%
Last declaration on 22 May 2026
Declarations133 total
1,745 shares0Common StockSEC:0001193125-26-237320:0
1,745 shares0Common StockSEC:0001193125-26-237321:0
1,745 shares0Common StockSEC:0001193125-26-237324:0
1,745 shares0Common StockSEC:0001193125-26-237325:0
2,326 shares0Common StockSEC:0001193125-26-237329:0
1,745 shares0Common StockSEC:0001193125-26-237333:0
1,745 shares0Common StockSEC:0001193125-26-237334:0
1,745 shares0Common StockSEC:0001193125-26-237339:0
1,745 shares0Common StockSEC:0001193125-26-237340:0
1,443 shares0Common StockSEC:0001193125-26-237344:0
16,107 shares@ US$190.0224.5% of flowCommon StockSEC:0001193125-26-067963:1
1,718 shares@ US$190.0237.0% of flowCommon StockSEC:0001193125-26-067969:1
1,210 shares@ US$190.0271.7% of flowCommon StockSEC:0001193125-26-067973:1
2,549 shares@ US$190.025.8% of flowCommon StockSEC:0001193125-26-067975:1
40,248 shares0Common StockSEC:0001193125-26-067963:0
5,864 shares0Common StockSEC:0001193125-26-067969:0
4,310 shares0Common StockSEC:0001193125-26-067973:0
7,848 shares0Common StockSEC:0001193125-26-067975:0
7,969 shares@ US$189.314318.1% of flowCommon StockSEC:0001193125-26-061949:0
7,576 shares@ US$131.48518.2% of flowCommon StockSEC:0001415889-25-020838:0
Canonical exit: 30 Oct 2025 (T+90)
42 shares@ US$109.65850.5% of flowCommon StockSEC:0001415889-25-020882:0
Canonical exit: 29 Oct 2025 (T+90)
1,531 shares0Common StockSEC:0001415889-25-014202:0
1,148 shares0Common StockSEC:0001415889-25-014206:0
1,148 shares0Common StockSEC:0001415889-25-014207:0
1,148 shares0Common StockSEC:0001415889-25-014209:0
25 of 133 declarations
About Align Technology Inc
Align Technology Inc. (ticker ALGN) is a U.S.-listed company traded on the NASDAQ, and for equity investors it is best understood as a global dental medtech platform rather than a pure orthodontics supplier. The company was founded in March 1997 and incorporated in Delaware in April 1997. It pioneered the invisible orthodontics category with Invisalign and later broadened its offering into digital dentistry through iTero intraoral scanners and exocad CAD/CAM software. Its global headquarters are in Tempe, Arizona, while major innovation and commercial functions have historically been anchored in San Jose, California, alongside regional operations in Europe and Asia-Pacific. In that sense, Align combines a U.S. corporate base with a highly international operating footprint.
Align’s business is organized around two core segments: Clear Aligner, centered on Invisalign, and Scanners and CAD/CAM Services, which includes iTero and exocad. This structure gives the company exposure to the full digital treatment workflow: digital impression capture, treatment planning, aligner fabrication, and restorative dentistry software and services. Align markets its solutions to orthodontists, general dentists, and laboratories, and management has consistently framed the opportunity as a broader digital transformation of dentistry. The company reports a presence in more than 100 markets worldwide, with Invisalign used by millions of patients and a large installed base of trained doctors, reflecting both scale and brand strength.
Read moreShow less
From a competitive standpoint, Align remains one of the most recognizable names in clear aligners and has built a strong moat through brand equity, clinical workflow integration, and an ecosystem approach. Its key products include Invisalign, ClinCheck treatment planning software, iTero Lumina scanners, and exocad software. The strategic logic is to expand from orthodontics into adjacent restorative and multidisciplinary workflows, capturing more of the dental chair-side and lab-side value chain. That is important because competition in aligners can be intense, but Align’s integrated hardware-software-platform model differentiates it from more narrowly focused peers.
Recent developments reinforce this positioning. In early February 2026, Align reported fourth-quarter and full-year 2025 results, highlighting better-than-expected revenue trends and improved profitability versus the prior year. The company also reiterated its 2026 outlook and announced a new share repurchase plan, underscoring continued confidence in cash generation. In spring 2026, Align showcased new Invisalign and iTero innovations at the AAO Annual Session, while management also flagged macro uncertainty, including tariff-related and demand-related risks. For investors, ALGN therefore offers a blend of category leadership, international exposure, and ongoing investment in digital dentistry innovation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
